International trade · 23/12/2021Updated: 10/17/2026 · 1 min read
Notice of Receipt of Complaint; Solicitation of Comments Relating to the Public Interest
Summary
The U.S. International Trade Commission has received a complaint about Adalimumab and is seeking public comments on the matter. The Commission is looking for input on any issues related to the public interest.